Search
Close this search box.
Search
Close this search box.

What metabolic diseases are caused by obesity?

What metabolic diseases are caused by obesity?

Science News

BioAge, a pioneering biotech firm, has recently announced the successful closure of its $170 million Series D financing round, marking a significant step forward in the development of innovative therapeutics for obesity and metabolic diseases. This funding round was led by Sofinnova and saw participation from notable healthcare investors, including Lilly and Amgen, who are key strategics in the field of obesity treatment.

The raised capital will primarily accelerate the clinical development of BioAge’s lead compound, azelaprag. This novel therapeutic agent shows promise in the treatment of obesity and other metabolic disorders. Azelaprag is an oral drug positioned to enhance weight loss both in terms of quantity and quality for patients undergoing GLP-1/incretin therapy for obesity. The anticipation is building for the initiation of a Phase 2 trial of azelaprag, slated for mid-2024.

What metabolic diseases are caused by obesity?

BioAge’s approach to combating metabolic disease is grounded in innovation. The company is leveraging the potential of azelaprag in conjunction with Zepbound. A therapy developed by global obesity leader Eli Lilly. This collaboration aligns with BioAge’s commitment to harnessing cutting-edge science and strategic partnerships to address complex health issues.

The uniqueness of azelaprag lies in its oral administration. Moreover, a feature that positions it as a potentially best-in-class weight loss medication. It also aims to improve body composition in patients taking GLP-1/incretin drugs for obesity. Additionally, the drug’s mechanism of action is particularly intriguing: it mimics the effects of apelin. Furthermore, a hormone released during exercise known to enhance metabolic and muscle function. BioAge’s research indicates that increased apelin activity becomes associated with longer lifespan and improved physical function in later life.

What metabolic diseases are caused by obesity?

Beyond azelaprag, BioAge is advancing its pipeline of therapeutics targeting metabolic and muscle aging. The company’s strategy includes the ongoing development of early-stage programs and the identification of novel targets for treating metabolic diseases. This endeavor, supported by BioAge’s unique discovery platform, built upon extensive human longevity data.

In conclusion, the development of therapies for metabolic diseases such as obesity stands of paramount importance!

effects of obesity: A review – PMC (nih.gov)

syndrome – Symptoms & causes – Mayo Clinic

Healthcare | Free Full-Text | The Related Treatments (mdpi.com)